The increased SOX2 expression is associated with poor patient prognosis in cancers of the oral cavity [5], esophagus [2], colorectal [6], lung, breast [7], liver [8] and prostate [9], whereas in gastric cancer, worse clinical outcome is correlated with the diminished SOX2 expression in cancer cells [10, 11]. Here, SOX2 is linked to gastric cancer.